Загрузка компании
Just reported
Q3 2026 results
From Penumbra's results release of 29 октября 2026 г.; its quarterly report has since been filed.
Revenue
Actual
410,1M $
+16 % y/y
+5,2 % q/qGuided
—
No guide given
EPS, GAAP
Actual
1,07 $
-8,5 % y/y
+22 % q/qGuided
—
No guide given
Operating income, GAAP
Actual
50,7M $
+3,9 % y/y
+24 % q/qGuided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Penumbra is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc129,2B $A+
SYKStryker Corp.118,9B $A+
EWEdwards Lifesciences Corporation60,9B $A+
GEHCGE Healthcare Technologies Inc.37B $A
GKOSGlaukos Corp14,6B $A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 окт. 2026 г.CBGraded C, now B
MCKMckesson Corporation4 нояб. 2026 г.BAGraded B, now A
CVSCVS Health Corp4 нояб. 2026 г.BAGraded B, now A- EWEdwards Lifesciences Corporation4 нояб. 2026 г.BAGraded B, now A
BIIBBiogen Inc.28 окт. 2026 г.BAGraded B, now A
Полная финансовая отчётность →
Построено по собственной отчётности Penumbra Inc, поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.
